Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

Core Viewpoint - Chengda Pharmaceutical Co., Ltd. plans to utilize up to 700 million yuan of idle funds for low-risk cash management to enhance capital efficiency [1][5]. Group 1: Investment Plan - The investment will be limited to low-risk, highly liquid financial products with a maturity of no more than 12 months, including agreed deposits, notice deposits, time deposits, structured deposits, and financial institution wealth management products [2]. - The total investment limit for the company and its subsidiaries is set at 700 million yuan, which can be used cyclically within the 12-month period [2]. Group 2: Risk Control - The company has established multiple risk control mechanisms, including a dynamic tracking mechanism to monitor product allocation and project progress, internal audit supervision for regular checks on investment projects, and the option for third-party audits as needed [3]. Group 3: Impact on the Company - The cash management initiative aims to ensure normal operations and fund safety while achieving value preservation and appreciation of idle funds, ultimately creating more returns for shareholders [5]. - The 700 million yuan investment amount will be assessed against the company's latest audited cash reserves to ensure alignment with the principle of "standardized operation and prudent management" [5]. Group 4: Review Process and Sponsor Opinion - The proposal has been approved by the board's audit committee and will be submitted for shareholder approval [6]. - The sponsor, Guangda Securities Co., Ltd., has confirmed that the necessary review procedures were followed and has no objections to the cash management initiative [6].

Company Overview - Chengda Pharmaceutical (SZ 301201) announced the convening of its sixth second board meeting on November 19, 2025, to discuss the proposal for the third extraordinary shareholders' meeting of 2025 [1] Financial Performance - For the year 2024, Chengda Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 55.67%, food manufacturing for 43.0%, other businesses for 0.69%, and trading revenue for 0.65% [1] - As of the report date, Chengda Pharmaceutical has a market capitalization of 8.9 billion yuan [1]

南财智讯11月19日电，诚达药业公告，公司于2025年11月19日召开第六届董事会第二次会议，审议通过 了《关于使用闲置募集资金进行现金管理的议案》。公司拟使用不超过人民币8.00亿元的暂时闲置募集 资金（含超募资金）进行现金管理，投资于安全性高、流动性好、期限不超过12个月的产品，包括但不 限于协定存款、通知存款、定期存款、结构性存款等现金管理类产品。使用期限自股东会审议通过之日 起12个月内有效，资金在额度范围内可滚动使用。该事项尚需提交公司股东会审议，不会影响募集资金 投资项目进度和公司正常生产经营。 ...

光大证券股份有限公司 关于诚达药业股份有限公司 使用闲置募集资金进行现金管理的核查意见 光大证券股份有限公司（以下简称"光大证券"、"保荐机构"）作为诚达 药业股份有限公司（以下简称"诚达药业"、"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募 集资金监管规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《深圳证券交易 所上市公司自律监管指引第 13 号——保荐业务》等相关法律法规和规范性文件 的规定，在持续督导期内，对诚达药业使用闲置募集资金（含超募资金）进行现 金管理的事项进行了审慎核查，并发表如下意见： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意诚达药业股份有限公司首次公开发行 股票注册的批复》（证监许可[2021]3857 号）同意注册，公司首次公开发行人民 币普通股(A 股)股票 24,174,035 股，发行价格为每股 72.69 元，募集资金总额为 175,721.06 万元，扣除发行费用共计 13,576.31 万元（不含税）后，募集资金净 额为 162 ...

（二）投资品种 光大证券股份有限公司 风险较低、流动性好、期限不超过 12 个月的产品（包括但不限于协定存款、 通知存款、定期存款、结构性存款、购买金融机构理财产品等）。产品不用于质 押，不用于以证券投资为目的的投资行为。 关于诚达药业股份有限公司 使用闲置自有资金进行现金管理的核查意见 光大证券股份有限公司（以下简称"光大证券"、"保荐机构"）作为诚达 药业股份有限公司（以下简称"诚达药业"、"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募 集资金监管规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《深圳证券交易 所上市公司自律监管指引第 13 号——保荐业务》等相关法律法规和规范性文件 的规定，在持续督导期内，对诚达药业使用闲置自有资金进行现金管理的事项进 行了审慎核查，并发表如下意见： 一、本次使用闲置自有资金进行现金管理的情况 （一）投资目的 为提高自有资金使用效率，在确保不影响正常经营和资金安全的情况下，公 司拟使用暂时闲置的自有资金进行现金管理，以更好的实现公司现金的保值 ...

诚达药业股份有限公司 证券代码：301201 证券简称：诚达药业 公告编号：2025-050 关于使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2025 年 11 月 19 日召开第 六届董事会第二次会议，审议通过了《关于使用闲置募集资金进行现金管理的议 案》。为充分利用公司闲置募集资金，提高资金利用效率，增加资金收益，公司 在确保不影响募集资金投资计划正常进行和募集资金安全的前提下，拟使用不超 过人民币 8 亿元（含本数）的闲置募集资金（含超募资金）进行现金管理，用于 购买安全性高、流动性好、期限不超过 12 个月的产品（包括但不限于协定存款、 通知存款、定期存款、结构性存款等现金管理类产品）。使用期限自公司股东会 审议通过之日起不超过 12 个月。在上述额度和期限范围内，资金可循环滚动使 用。该议案尚需公司股东会审议，同时公司董事会将提请股东会授权公司经营管 理层在上述额度内行使该项决策权并签署相关协议及办理相关具体事宜。具体情 况如下： 一、募集资金的基本情况 经中国证券监 ...

为提高自有资金使用效率，在确保不影响正常经营和资金安全的情况下，公 司拟使用暂时闲置的自有资金进行现金管理，以更好的实现公司现金的保值增值， 保障公司股东的利益。 证券代码：301201 证券简称：诚达药业 公告编号：2025-051 诚达药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2025 年 11 月 19 日召开公 司第六届董事会第二次会议，审议通过了《关于使用闲置自有资金进行现金管理 的议案》并同意将此议案提交股东会审议。为提高闲置自有资金的使用效率，增 加公司资金收益，在不影响公司正常经营及确保资金安全的情况下，同意公司及 子公司使用不超过人民币 7 亿元（含本数）的闲置自有资金进行现金管理，用于 购买风险较低、流动性好、期限不超过 12 个月的产品（包括但不限于协定存款、 通知存款、定期存款、结构性存款、购买金融机构理财产品等）。使用期限自公 司股东会审议通过之日起不超过 12 个月。在上述额度和期限范围内，资金可循 环滚动使用。本议案尚需提交 ...

证券代码：301201 证券简称：诚达药业 公告编号：2025-052 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： 诚达药业股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 （1）现场会议时间：2025 年 12 月 5 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 5 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票 的具体时间为 2025 年 12 月 5 日 9:15 至 15:00 的任意时间。 7、出席对象： （1）在股权登记日持有公司已发行有表决权股份的股东或其代理人； 截至 2 ...